Monoamine oxidase: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(New page: In biology, '''monoamine oxidase''' is "an enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in ...)
 
imported>Meg Taylor
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{subpages}}
In [[biology]], '''monoamine oxidase''' is "an [[enzyme]] that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of [[catecholamine]]s and [[serotonin]] in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.<ref>{{MeSH}}</ref>
In [[biology]], '''monoamine oxidase''' is "an [[enzyme]] that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of [[catecholamine]]s and [[serotonin]] in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.<ref>{{MeSH}}</ref>


Line 11: Line 12:
[[Monoamine oxidase inhibitor]]s are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."<ref>{{MeSH|Monoamine oxidase inhibitors}}</ref> Reversible inhibitor of monoamine oxidase A (RIMA)  
[[Monoamine oxidase inhibitor]]s are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."<ref>{{MeSH|Monoamine oxidase inhibitors}}</ref> Reversible inhibitor of monoamine oxidase A (RIMA)  
   
   
[[Clorgyline]] selectivly inhibits MAO-A.<ref name="isbn0-07-145153-6"/>
[[Clorgyline]] selectively inhibits MAO-A.<ref name="isbn0-07-145153-6"/>


[[Deprenyl]] selectivly inhibits MAO-B.<ref name="isbn0-07-145153-6"/> [[Rasagiline]], used to treat [[Parkinson Disease]], is an inhibitor of Type B monoamine oxidase.<ref>N Engl J Med 2009; 361:1268-1278, Sep 24, 2009. PMID 19776408</ref>
[[Deprenyl]] selectively inhibits MAO-B.<ref name="isbn0-07-145153-6"/> [[Rasagiline]], used to treat [[Parkinson's disease]], is an inhibitor of Type B monoamine oxidase.<ref>N Engl J Med 2009; 361:1268-1278, Sep 24, 2009. PMID 19776408</ref>


==References==
==References==
<references/>
{{reflist}}

Latest revision as of 12:24, 2 October 2013

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In biology, monoamine oxidase is "an enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation.[1]

Classification

Type A monoamine oxidase (MAO-A)

MAO-A deaminates norepinephrine and serotonin.[2]

Type B monoamine oxidase (MAO-B)

MAO-B deminates phenylethylamines.[2]

Pharmacology

Monoamine oxidase inhibitors are "a chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines."[3] Reversible inhibitor of monoamine oxidase A (RIMA)

Clorgyline selectively inhibits MAO-A.[2]

Deprenyl selectively inhibits MAO-B.[2] Rasagiline, used to treat Parkinson's disease, is an inhibitor of Type B monoamine oxidase.[4]

References

  1. Anonymous (2024), Monoamine oxidase (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. 2.0 2.1 2.2 2.3 Katzung, Bertram G. (2006). “30. Antidepressant agents”, Basic and Clinical Pharmacology, 10th. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6. 
  3. Anonymous (2024), Monoamine oxidase inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.
  4. N Engl J Med 2009; 361:1268-1278, Sep 24, 2009. PMID 19776408